

Clinical Trial Protocol

Iranian Registry of Clinical Trials

03 Jun 2026

Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis: a randomized clinical trial

Protocol summary

Study aim

To assess the effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis

Design

This is a randomized clinical trial with control group, phase III, in which eligible patients will be randomly assigned through the block randomization to the intervention and control groups

Settings and conduct

This study will be performed in the Besat Hospital in Hamadan city on 32 eligible patients. The patients will be randomly assigned to the intervention and control groups through the block randomization. This study will be performed without blinding.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Age 18 to 80 years Cerebral venous thrombosis Exclusion criteria: Contraindication o anticoagulant therapy Brain tumor

Intervention groups

Intervention group: Rivaroxaban tablets 15 mg twice a day for 3 weeks and then 20 mg daily for 6 months
Control group: Apixaban tablets 10 mg twice a day for 3 weeks and then 5 mg twice a day for 6 months

Main outcome variables

Primary outcome: Functional impairment Secondary outcome: Complication of cerebral hemorrhage

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20120215009014N451**
Registration date: **2022-12-24, 1401/10/03**
Registration timing: **registered_while_recruiting**

Last update: **2022-12-24, 1401/10/03**

Update count: **0**

Registration date

2022-12-24, 1401/10/03

Registrant information

Name

Jalal Poorolajal

Name of organization / entity

Department of Epidemiology & Biostatistics Hamadan University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 81 1838 0090

Email address

poorolajal@umsha.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2022-12-22, 1401/10/01

Expected recruitment end date

2023-09-22, 1402/06/31

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis: a randomized clinical trial

Public title

Effect of rivaroxaban versus apixaban on treatment of cerebral venous thrombosis

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Age 18 to 80 years Cerebral venous thrombosis

Exclusion criteria:

Contraindication o anticoagulant therapy Brain tumor

Age

From **18 years** old to **80 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **32**

Randomization (investigator's opinion)

Randomized

Randomization description

The patients will be randomly assigned to intervention and control groups using block randomization. For this purpose, we will prepare four sheets of paper, writing on two sheets the name of the intervention and on the other two sheets the name of the control. The paper sheets will be pooled, placed in a container, and randomly drawn one at a time for each patient without replacement until all four sheets are drawn. The four paper sheets will be then placed back into the container, and this action repeated until the sample size is reached.

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics Committee of Hamadan University of Medical Sciences

Street address

Vice-chancellor for Research and Technology,
Hamadan University of Medical Sciences, Shahid
Fahmideh Ave

City

Hamadan

Province

Hamadan

Postal code

6517838695

Approval date

2022-06-27, 1401/04/06

Ethics committee reference number

IR.UMSHA.REC.1401.321

Health conditions studied

1

Description of health condition studied

Cerebral venous thrombosis

ICD-10 code

I63.00

ICD-10 code description

Cerebral infarction due to thrombosis of unspecified precerebral artery

Primary outcomes

1

Description

Functional impairment

Timepoint

90 days after intervention

Method of measurement

Using modified Rankin Scale (mRS)

Secondary outcomes

1

Description

Complication of cerebral hemorrhage

Timepoint

During the 6-month follow-up period

Method of measurement

Using brain CT scan

Intervention groups

1

Description

Intervention group: Rivaroxaban tablets 15 mg twice a day for 3 weeks and then 20 mg daily for 6 months

Category

Treatment - Drugs

2

Description

Control group: Apixaban tablets 10 mg twice a day for 3 weeks and then 5 mg twice a day for 6 months

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Besat Hospital in Hamadan city

Full name of responsible person

Dr Maryam Ghasemi

Street address

Besat Hospital, Shahed Square

City

Hamadan

Province

Hamadan

Postal code

6517838695

Phone

+98 81 3364 0030

Email

maryam.gh1989@yahoo.com

Sponsors / Funding sources**1****Sponsor****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Dr. Reza Shokoohi

Street address

Hamadan University of Medical Sciences, Shahid Fahmideh Ave

City

Hamadan

Province

Hamadan

Postal code

6517838695

Phone

+98 81 3838 0717

Email

info.research@umsha.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

Yes

Title of funding source

Hamedan University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Academic

Person responsible for general inquiries**Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Dr Maryam Ghasemi

Position

Resident of Neurology

Latest degree

Medical doctor

Other areas of specialty/work

Neurology

Street address

School of Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

City

Hamadan

Province

Hamadan

Postal code

6517838695

Phone

+98 81 3838 0572

Email

maryam.gh1989@yahoo.com

Person responsible for scientific inquiries**Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Dr. Mojtaba Khazaei

Position

Neurologist

Latest degree

Medical doctor

Other areas of specialty/work

Neurology

Street address

School of Medicine, Hamadan University of Medical Sciences, Shahid Fahmideh Ave.

City

Hamadan

Province

Hamadan

Postal code

6517838695

Phone

+98 81 3838 0572

Email

khazaeimojtaba@yahoo.com

Person responsible for updating data**Contact****Name of organization / entity**

Hamedan University of Medical Sciences

Full name of responsible person

Dr. Jalal Poorolajal

Position

Professor of Epidemiology

Latest degree

Ph.D.

Other areas of specialty/work

Epidemiology

Street address

School of Public Health, Hamadan University of

Medical Sciences, Shahid Fahmideh Ave

City

hamadan

Province

Hamadan

Postal code

6517838695

Phone

+98 81 3838 0090

Email

poorolajal@umsha.ac.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to make this available